WO1998006440A3 - Phenotypic conversion of cells mediated by external guide sequences - Google Patents
Phenotypic conversion of cells mediated by external guide sequences Download PDFInfo
- Publication number
- WO1998006440A3 WO1998006440A3 PCT/US1997/014457 US9714457W WO9806440A3 WO 1998006440 A3 WO1998006440 A3 WO 1998006440A3 US 9714457 W US9714457 W US 9714457W WO 9806440 A3 WO9806440 A3 WO 9806440A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- drug
- external guide
- guide sequences
- sensitive
- Prior art date
Links
- 238000006243 chemical reaction Methods 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 12
- 239000003814 drug Substances 0.000 abstract 8
- 229940079593 drug Drugs 0.000 abstract 8
- 238000000034 method Methods 0.000 abstract 7
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- 230000001580 bacterial effect Effects 0.000 abstract 4
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 3
- 241000894006 Bacteria Species 0.000 abstract 2
- 102000053642 Catalytic RNA Human genes 0.000 abstract 2
- 108090000994 Catalytic RNA Proteins 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108091092562 ribozyme Proteins 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 241000195493 Cryptophyta Species 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- -1 cationic porphyrin Chemical class 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 230000001268 conjugating effect Effects 0.000 abstract 1
- 238000002651 drug therapy Methods 0.000 abstract 1
- 244000000013 helminth Species 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 150000004032 porphyrins Chemical class 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/126—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes involving RNAse P
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed are a method and compositions for delivering nucleic acids to bacterial cells. The method does not require manipulation of the bacteria and is therefore particularly suited to delivery of nucleic acids to bacteria in natural environments, including inside animal bodies. The method generally involves conjugating the nucleic acid to be delivered with a cationic porphyrin and bringing the conjugate and the target bacterial cells into contact. Both the porphyrin and conjugated nucleic acid are taken up by the bacterial cells and the nucleic acid can then have a biological effect on the cells. Specifically disclosed is a method for converting drug-resistant bacterial cells to drug-sensitive cells by delivery of external guide sequences to the cells which then promote cleavage of RNA molecules involved in conferring the drug-resistant phenotype on the cells. The drug-resistant phenotype of the cells is thus converted to a drug-sensitive phenotype. The drug-sensitive cells are then susceptible to drug therapy. Also disclosed is a method and compositions for killing eukaryotic pathogens or converting drug-resistant eukaryotic cells to drug-sensitive cells. The method involves the delivery of external guide sequences, ribozymes, or vectors encoding external guide sequences or ribozymes, to eukaryotic cells. Preferred target eukaryotic cells for the disclosed method include algae, protozoa, fungi, slime mold, and cells of helminths.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU39844/97A AU3984497A (en) | 1996-08-16 | 1997-08-15 | Phenotypic conversion of cells mediated by external guide sequences |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2367596P | 1996-08-16 | 1996-08-16 | |
| US60/023,675 | 1996-08-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1998006440A2 WO1998006440A2 (en) | 1998-02-19 |
| WO1998006440A3 true WO1998006440A3 (en) | 1998-06-25 |
Family
ID=21816556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/014457 WO1998006440A2 (en) | 1996-08-16 | 1997-08-15 | Phenotypic conversion of cells mediated by external guide sequences |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU3984497A (en) |
| WO (1) | WO1998006440A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9912965D0 (en) * | 1999-06-03 | 1999-08-04 | Oxford Biomedica Ltd | In vivo selection method |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993013740A2 (en) * | 1991-12-31 | 1993-07-22 | Worcester Foundation For Experimental Biology | Antiparasitic oligonucleotides active against drug resistant malaria |
| WO1994012643A1 (en) * | 1992-12-03 | 1994-06-09 | Unisearch Ltd. | Nucleotide sequence encoding carbamoyl phosphate synthetase ii |
| WO1995027480A1 (en) * | 1994-04-12 | 1995-10-19 | Innovir Laboratories, Inc. | Heme-bearing microparticles for targeted delivery of drugs |
| WO1996008558A1 (en) * | 1994-09-12 | 1996-03-21 | City Of Hope | Modulation of drug radiation resistant genes |
| WO1996021731A2 (en) * | 1995-01-13 | 1996-07-18 | Innovir Laboratories, Inc. | Stabilized external guide sequences |
| WO1996021665A1 (en) * | 1995-01-13 | 1996-07-18 | Board Of Regents, The University Of Texas System | Turcasarins, novel expanded porphyrins, and uses thereof |
| WO1997033622A2 (en) * | 1996-03-14 | 1997-09-18 | Innovir Laboratories, Inc. | Delivery of nucleic acids by porphyrins |
-
1997
- 1997-08-15 WO PCT/US1997/014457 patent/WO1998006440A2/en active Application Filing
- 1997-08-15 AU AU39844/97A patent/AU3984497A/en not_active Abandoned
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993013740A2 (en) * | 1991-12-31 | 1993-07-22 | Worcester Foundation For Experimental Biology | Antiparasitic oligonucleotides active against drug resistant malaria |
| WO1994012643A1 (en) * | 1992-12-03 | 1994-06-09 | Unisearch Ltd. | Nucleotide sequence encoding carbamoyl phosphate synthetase ii |
| WO1995027480A1 (en) * | 1994-04-12 | 1995-10-19 | Innovir Laboratories, Inc. | Heme-bearing microparticles for targeted delivery of drugs |
| WO1996008558A1 (en) * | 1994-09-12 | 1996-03-21 | City Of Hope | Modulation of drug radiation resistant genes |
| WO1996021731A2 (en) * | 1995-01-13 | 1996-07-18 | Innovir Laboratories, Inc. | Stabilized external guide sequences |
| WO1996021665A1 (en) * | 1995-01-13 | 1996-07-18 | Board Of Regents, The University Of Texas System | Turcasarins, novel expanded porphyrins, and uses thereof |
| WO1997033622A2 (en) * | 1996-03-14 | 1997-09-18 | Innovir Laboratories, Inc. | Delivery of nucleic acids by porphyrins |
Non-Patent Citations (6)
| Title |
|---|
| GUERRIER-TAKADA C ET AL: "Phenotypic conversion of drug - resistant bacteria to drug sensitivity.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997 AUG 5) 94 (16) 8468-72., XP002052175 * |
| GUERRIER-TAKADA, C. ET AL.: "Artificial regulation of gene expression in Escherichia coli by RNase P", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 92, November 1995 (1995-11-01), WASHINGTON US, pages 11115 - 11119, XP002052174 * |
| HARTMANN R K ET AL: "TOWARDS A NEW CONCEPT OF GENE INACTIVATION: SPECIFIC RNA CLEAVAGE BY ENDOGENOUS RIBONUCLEASE P", BIOTECHNOLOGY ANNUAL REVIEW, vol. 1, 1995, pages 215 - 265, XP000609333 * |
| HIROSHI KIJIMA ET AL: "THERAPEUTIC APPLICATIONS OF RIBOZYMES", PHARMACOLOGY AND THERAPEUTICS, vol. 68, no. 2, 1995, pages 247 - 267, XP000612090 * |
| KOBAYASHI H ET AL: "Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme.", CANCER RESEARCH, (1994 MAR 1) 54 (5) 1271-5., XP002062947 * |
| MERCHAT, M. ET AL.: "Meso-substituted cationic porphyrins as efficient photosensitizers of Gram-positive and Gram-negative bacteria", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B: BIOLOGY, vol. 32, February 1996 (1996-02-01), pages 153-157, XP002052173 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU3984497A (en) | 1998-03-06 |
| WO1998006440A2 (en) | 1998-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0004728A1 (en) | Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor | |
| EP0827410A4 (en) | METHOD FOR INTRODUCING AND EXPRESSING GENES IN ANIMAL CELLS | |
| EP1210123A4 (en) | Single-stranded oligodeoxynucleotide mutational vectors | |
| CA2325351A1 (en) | Non-stochastic generation of genetic vaccines and enzymes | |
| WO2000071096A3 (en) | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases | |
| HUP0004589A1 (en) | Improved method for transferring nucleic acid into the striped muscle and combination therefor | |
| WO1997042975A3 (en) | Chitosan related compositions for delivery of nucleic acids into a cell | |
| WO1997038729A8 (en) | In vivo gene transfer methods for wound healing | |
| EP1549352A4 (en) | Methods for delivery of nucleic acids | |
| EP1390049A4 (en) | Compositions for treating animal diseases and syndromes | |
| WO1999046366A8 (en) | Uses for humane non-autologous mesenchymal stem cells | |
| MX9605716A (en) | Methods and compositions for treatment of restenosis and cancer using ribozymes. | |
| WO2002024232A3 (en) | Pei: dna vector formulations for in vitro and in vivo gene delivery | |
| HK1047129A1 (en) | Sequence-specific dna recombination in eukaryotic cells | |
| WO2004108208A3 (en) | Methods and apparatus for conversion of eukaryotic cells by application of electric and magnetic fields | |
| WO1998006440A3 (en) | Phenotypic conversion of cells mediated by external guide sequences | |
| EP0763205A4 (en) | Nucleic acid sequences controlling lung cell-specific gene expression | |
| WO2003059262A3 (en) | Method and composition for treating and preventing hiv infection and aids | |
| AU2002346803A1 (en) | Genes encoding for carbon metabolism and energy-producing proteins | |
| FR2801592B1 (en) | PHOSPHORUS DENDRIMETERS AND THEIR APPLICATIONS AS TRANSFECTION AGENTS | |
| Shcherbakova et al. | Camptothecin enhances random integration of transfected DNA into the genome of mammalian cells | |
| AU2806597A (en) | Human DNase II | |
| AU1248602A (en) | Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids | |
| WO2001073001A3 (en) | Establishment of cellular manipulations which enhance oligo-mediated gene targeting | |
| MXPA03001884A (en) | Vp22 protein/nucleic acid aggregates, uses thereof. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998510090 Format of ref document f/p: F |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |